-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BB-1701 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BB-1701 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BB-1701 in Solid Tumor Drug Details: BB-1701 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BTXA-51 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BTXA-51 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BTXA-51 in B-Cell Non-Hodgkin Lymphoma Drug Details: BTXA-51 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ianalumab in Systemic Lupus Erythematosus
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ianalumab in Systemic Lupus Erythematosus report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ianalumab in Systemic Lupus Erythematosus Drug Details: Ianalumab is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nisevokitug in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nisevokitug in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nisevokitug in Triple-Negative Breast Cancer (TNBC) Drug Details: Nisevokitug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRG-002 in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRG-002 in Urethral Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRG-002 in Urethral Cancer Drug Details: MRG-002 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Relatlimab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Hepatocellular Carcinoma Drug Details: Relatlimab (BMS-986016) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BTX-1188 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BTX-1188 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BTX-1188 in Refractory Acute Myeloid Leukemia Drug Details:BTX-1188 is under development...